{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Dose Expansion. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.","groups":[{"description":"Dose Escalation: Level 1 dose of 80 mg enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).","id":"OG000","title":"Dose Escalation: Level 1 Dose"},{"description":"Dose Escalation - Level 2 dose of 160 mg enzalutamide (orally) with standard dose of cisplatin and gemcitabine via intravenous (IV).","id":"OG001","title":"Dose Escalation: Level 2 Dose"},{"description":"Dose Expansion: Enzalutamide at MTD (160 mg) with standard doses of cisplatin and gemcitabine.","id":"OG002","title":"Dose Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants evaluable at time of analysis.","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Overall Response Rate (ORR): Complete Response (CR) + Partial Response (PR)","type":"SECONDARY","unitOfMeasure":"Participants"}